Ieq Capital LLC Takes $934,000 Position in PROCEPT BioRobotics Corporation $PRCT

Ieq Capital LLC bought a new position in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 41,384 shares of the company’s stock, valued at approximately $934,000. Ieq Capital LLC owned about 0.07% of PROCEPT BioRobotics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Versant Capital Management Inc raised its position in PROCEPT BioRobotics by 994.5% during the second quarter. Versant Capital Management Inc now owns 1,193 shares of the company’s stock valued at $27,000 after acquiring an additional 1,084 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its position in PROCEPT BioRobotics by 436.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after purchasing an additional 746 shares in the last quarter. Center for Financial Planning Inc. acquired a new stake in shares of PROCEPT BioRobotics during the 4th quarter worth approximately $40,000. Cache Advisors LLC acquired a new stake in shares of PROCEPT BioRobotics during the 1st quarter worth approximately $42,000. Finally, Essential Partners LLC increased its holdings in shares of PROCEPT BioRobotics by 7,071.4% during the 1st quarter. Essential Partners LLC now owns 2,008 shares of the company’s stock valued at $50,000 after purchasing an additional 1,980 shares in the last quarter. 89.46% of the stock is owned by institutional investors and hedge funds.

PROCEPT BioRobotics Trading Down 2.2%

Shares of NASDAQ:PRCT opened at $20.60 on Friday. PROCEPT BioRobotics Corporation has a 1 year low of $16.67 and a 1 year high of $42.43. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -10.62 and a beta of 0.89. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. The business’s 50 day moving average price is $20.34 and its 200-day moving average price is $23.96.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The company had revenue of $94.50 million during the quarter, compared to analysts’ expectations of $92.77 million. PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.PROCEPT BioRobotics’s revenue was up 19.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.35) EPS. On average, equities research analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Larry L. Wood bought 23,900 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was acquired at an average price of $20.85 per share, with a total value of $498,315.00. Following the completion of the purchase, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at approximately $498,315. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold a total of 1,000 shares of company stock valued at $28,480 in the last quarter. 4.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Piper Sandler decreased their target price on shares of PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday, August 5th. Wells Fargo & Company cut shares of PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 price objective for the company. in a report on Wednesday, August 5th. William Blair downgraded shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Robert W. Baird set a $20.00 price objective on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $20.00 target price on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, PROCEPT BioRobotics presently has an average rating of “Hold” and an average target price of $28.00.

Trending Headlines about PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Negative Sentiment: Several firms reiterated that investors who purchased PROCEPT shares between February 28, 2024, and February 25, 2026, have until September 22, 2026, to seek appointment as lead plaintiff. The concentration of deadline notices increases visibility around the litigation and adds a legal overhang for the stock. Rosen Law Firm deadline notice
• Negative Sentiment: The lawsuits allege that PROCEPT did not adequately disclose the use of discounts and late-quarter bulk sales to pull forward handpiece demand, potentially contributing to excess inventory at customers. The complaints also allege that investors were later informed about field-inventory optimization and weaker procedure or handpiece sales. These allegations have not been proven in court. SueWallSt investor alert
• Negative Sentiment: Hagens Berman and other firms characterized the case as following repeated handpiece-sales underperformance and disclosures of excess customer inventory. One notice cited an approximately 18% decline associated with inventory-related disclosures, while another said the shares had fallen more than 75% from their class-period high. Hagens Berman investor alert
• Neutral Sentiment: The repeated announcements primarily seek to recruit investors and establish a lead plaintiff; they do not represent new operating results or a final finding of wrongdoing. However, the litigation could create legal costs, management distraction, and uncertainty regarding PROCEPT’s sales practices and demand outlook. Howard G. Smith deadline alert

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.